DSIP

Overview

Naturally occurring peptide that promotes deep sleep and stress reduction.

Reported benefits

Improved deep sleep, stress reduction, recovery enhancement, pain reduction

Protocols & dosing

Typical dosage: 100-300 mcg (before bed).

Detailed dosing protocols have not yet been catalogued.

FDA & legal status

DSIP is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed DSIP from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place DSIP on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 2 — July 24, 2026. PCAC agenda: DSIP (Emideltide), Semax, Epitalon. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

Vendor information

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Side effects & safety

Reported side effects: Very well-tolerated, possible grogginess

References

No external sources have been catalogued for this article yet.